Reported about 8 hours ago
Merck's fourth quarter earnings exceeded expectations, generating $15.6 billion in global sales and $64.2 billion for the year, but the stock fell over 10% in pre-market trading due to disappointing guidance for 2025, which projected only slight revenue growth. Analysts express concerns over Merck's long-term strategy amid competition and patent expirations.
Source: YAHOO